Anelia V. Delcheva

Anelia V. Delcheva

Morrison & Foerster LLP

Contact  |  View Bio  |  RSS

Latest Publications

Share:

Socially Aware - Volume 5, Issue 7 - December 2014

In This Issue: - What’s in a Like? - R.I.P.: The Facebook “Like” Gate - Facebook Dislikes Fake Likes - Privacy in the Cloud: A Legal Framework for Moving Personal Data to the Cloud - Click...more

12/17/2014 - Advertising Clickwrap Agreements Cloud-Based Services COPPA Counterfeiting Data Protection EU Facebook Infringement Internet Mobile Apps Social Media Terms of Use UK Websites

Implementing and Enforcing Online Terms of Use

Operators of social media platforms and other websites must manage a large number of risks arising from their interactions with users. In an effort to maintain a degree of predictability and mitigate some of those risks,...more

10/6/2014 - Barnes and Noble Browsewrap Agreement Clickwrap Agreements Contract Formation Disclaimers Dispute Resolution Facebook Risk Mitigation Social Media Terms of Use Websites

Socially Aware - Volume 4, Issue 2 - December 2013

In This Issue: Peering Into the Future: Google Glass and the Law; Ownership of Business-Related Social Media Accounts; Two Circuits Address the First Amendment Status of Facebook Activity; Collaborative Consumption –...more

12/23/2013 - Advertising Behavioral Advertising First Amendment Google Google Glass Internet Technology Terms of Use

MoFo BioMeter - Vol. 2, Issue 4, November 2013 - Q3 BioMeter Shows Strong Early Stage Deals

The average BioMeter value in the third quarter of 2013 was $30.4 million, an increase from the $22.2 million value in the second quarter. Like last quarter, Phase 1 and Phase 2 transactions showed very strong results, with...more

11/26/2013 - Biotechnology Pharmaceutical Prescription Drugs

MoFo BioMeter - Vol. 2, Issue 3, August 2013 - Q2 BioMeter Encouraging for Products from Early Development through Phase 2

The average BioMeter value in the second quarter of 2013 was $22.2 million, an increase from the $16.3 million value in the first quarter (excluding BMS/Rickets and AZ/Moderna), and down from $59.4 million in the first...more

8/29/2013 - Biotechnology Pharmaceutical

MoFo BioMeter - Volume 2, Issue 2: May 2013 - Flat BioMeter Value and Decline in Deal Volume are Hallmarks of Q1

The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter. In the...more

5/31/2013 - Biotechnology OTC Pharmaceutical Prescription Drugs Valuation

MoFo BioMeter - Volume 2, Issue 2: May 2013 - Flat BioMeter Value and Decline in Deal Volume are Hallmarks of Q1

The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter. In the...more

5/22/2013 - Biotechnology

MoFo BioMeter - Volume 2, Issue 1: February 2013

Phase 2 Deals Dominate Q4 and Full Year 2012 - Morrison & Foerster is pleased to release the MoFo BioMeter for the fourth quarter of 2012 and for the full year of 2012. The fourth quarter of 2012 saw an uptick in...more

2/25/2013 - Biotechnology Life Sciences

Introducing the MoFo BioMeter

Morrison & Foerster is pleased to introduce the MoFo BioMeter™, an index developed to measure the health of the biotechnology industry. BioMeter takes the pulse of the industry by looking at a key measure of deal...more

12/15/2012 - Biotechnology Life Sciences

10 Results
|
View per page
Page: of 1